IsoPlexis Corp (ISO) News

IsoPlexis Corp (ISO): $1.92

-0.13 (-6.34%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Filter ISO News Items

ISO News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

Latest ISO News From Around the Web

Below are the latest news stories about IsoPlexis Corp that investors may wish to consider to help them evaluate ISO as an investment opportunity.

Earnings Scheduled For March 2, 2022

Companies Reporting Before The Bell • SIGNA Sports United (NYSE: SSU ) is expected to report quarterly loss at $0.04 per share on revenue of $283.61 million. • IsoPlexis (NASDAQ: ISO ) is likely to report quarterly loss at $0.68 per share on revenue of $5.45 million. • Innoviz Technologies (NASDAQ: INVZ ) is likely to report quarterly loss at $0.18 per share on revenue of $2.93 million. • International Seaways (NYSE: INSW ) is expected to report quarterly loss at $0.36 per share on revenue of $102.60 million. • Dine Brands Global (NYSE: DIN ) is estimated to report quarterly earnings at $1.27 per share on revenue of $236.67 million. • Dollar Tree (NASDAQ: DLTR ) is expected to report quarterly earnings at $1.77 per share on revenue of $7.12 billion. • Valens Semiconductor (NYSE: VLN ) i...

Benzinga | March 2, 2022

IsoPlexis Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Revenue Outlook for 2022

2021 revenue increased 66% over prior year period 2021 revenue increased 66% over prior year period

GlobeNewswire | March 2, 2022

IsoPlexis'' (ISO) CEO Sean Mackay on Q4 2021 Results - Earnings Call Transcript

No summary available.

Seeking Alpha | March 2, 2022

IsoPlexis Corporation 2021 Q4 - Results - Earnings Call Presentation

No summary available.

Seeking Alpha | March 2, 2022

IsoPlexis GAAP EPS of -$8.99, revenue of $17.25M beats by $0.13M

IsoPlexis press release (ISO): FY GAAP EPS of -$8.99.Revenue of $17.25M (+66.2% Y/Y) beats by $0.13M.2022 Guidance: IsoPlexis expects full year 2022 revenue to be in the range of…

Seeking Alpha | March 2, 2022

IsoPlexis to Report Fourth Quarter and Full Year 2021 Financial Results on March 2, 2022

BRANFORD, Conn., Feb. 16, 2022 (GLOBE NEWSWIRE) -- IsoPlexis Corporation (Nasdaq: ISO), the Superhuman Cell Company, today announced it will report financial results for the fourth quarter and full year 2021 before market open on Wednesday, March 2, 2022. Company management will be webcasting a corresponding conference call beginning at 5:30 a.m. Pacific Time / 8:30 a.m. Eastern Time.

GlobeNewswire | February 16, 2022

IsoPlexis to Participate in Three Upcoming Investor Conferences

BRANFORD, Conn., Feb. 11, 2022 (GLOBE NEWSWIRE) -- IsoPlexis Corporation (Nasdaq: ISO), the Superhuman Cell Company, today announced the company will be participating in the following investor conferences. 11th Annual SVB Leerink Global Healthcare Conference, VirtualFireside Chat on Wednesday, February 16th at 7:00 a.m. Pacific Time / 10:00 a.m. Eastern TimeCowen 42nd Annual Health Care Conference, Virtual Fireside Chat on Wednesday, March 9th at 6:10 a.m. Pacific Time / 9:10 a.m. Eastern TimeBa

Yahoo | February 11, 2022

IsoPlexis'' Immune Monitoring Helps Identify Early Factors of Long COVID

IsoPlexis Corporation (NASDAQ: ISO ) has announced the publication of a study in Cell, led by the Institute for Systems Biology and Seattle COVID consortium. In the study, the researchers used IsoPlexis'' single-cell functional proteomics platform to identify factors that may predict sustained disease after COVID-19 infection, also known as … Full story available on Benzinga.com

Benzinga | February 10, 2022

IsoPlexis' Immune Monitoring Helps Identify Early Factors of Long COVID

IsoPlexis Corporation (NASDAQ: ISO) has announced the publication of a study in Cell, led by the Institute for Systems Biology and Seattle COVID consortium. In the study, the researchers used IsoPlexis' single-cell functional proteomics platform to identify factors that may predict sustained disease after COVID-19 infection, also known as Long COVID. Authors followed 309 patients from initial clinical diagnosis to early-stage recovery from acute disease, spanning up to 2-3 months post-diagnosis,

Yahoo | February 10, 2022

IsoPlexis’ Immune Monitoring Helps Identify Early Factors of Long COVID in Cell Publication

Single-cell functional proteomics identifies biological factors and immune cell types that drive Long COVID in convalescent COVID-19 patientsBRANFORD, Conn., Feb. 10, 2022 (GLOBE NEWSWIRE) -- IsoPlexis Corporation (NASDAQ: ISO), the Superhuman Cell Company, today announced the publication of a study in Cell, led by the Institute for Systems Biology and Seattle COVID consortium, in which researchers used IsoPlexis’ single-cell functional proteomics platform to identify factors that may predict su

Yahoo | February 10, 2022


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.5778 seconds.